Millennium highlights updated survival results from the pivotal ADCETRIS ® (brentuximab vedotin) in patients with Hodgkins lymphoma trial in relapse or refractory
Millennium highlights pivotal with ADCETRIS ® (brentuximab vedotin) updated survival results from the test in patients with relapse or refractory Hodgkin’s lymphoma -ADCETRIS ® presents promising results to follow responding patients to treatment after a follow-up of 26.5 months, so it could not be determined yet the median overall survival in the study – – data is just presented at the seventeenth annual meeting of the European Congress of Hematology – CambridgeMassachusetts (USA).(UU.), June 2012.- the Millennium, the Takeda Oncology Company-owned company, has announced the updated data from the pivotal trial phase II, which discusses the treatment in monotherapy brentuximab vedotin in patients with lymphoma relapse or refractory Hodgkin after a bone marrow transplant. (TAMO). Results from the study are promising to continue responding patients to treatment after a follow-up of 26.5 months, so it could not be determined yet the median overall survival in the study. The data have been recently during an oral presentation at the seventeenth annual meeting of European Hematology Association (EHA), from 14 to 17 June 2012, in Amsterdam. Brentuximab vedotin is an antibody conjugated to a drug, aimed at the receiver CD30, most types of Hodgkin Lymphoma-specific marker. ’patients with Hodgkin’s lymphoma, multiple prior treatments that fall after receiving an autologous bone marrow transplant often have poor prognosis and there is a great need for effective therapeutic options’, argues Dr. Scott Smith, of...
Read More